 |
80 Diseases |  |
2 Trials |
|
2 Trials |  |
151 News |  |
| «123» |
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Journal: Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents in Patients with Coronary Artery Disease: Primary Results from the BIONICS Trial. (Pubmed Central) - Oct 7, 2017
P2
In the present trial, which allowed broad inclusion criteria, the novel RESs met the prespecified criteria for noninferiority compared with zotarolimus-eluting stents for the primary end point of target lesion failure at 12 months and had similar measures of late lumen loss. These findings support the safety and efficacy of RESs in patients who are representative of clinical practice.
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion: Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids (clinicaltrials.gov) - Aug 30, 2017
P1, N=24, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
These findings support the safety and efficacy of RESs in patients who are representative of clinical practice. Active, not recruiting --> Completed
- | Journal: IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. (Pubmed Central) - Jul 21, 2017
We discovered new druggable targets expressed by chemoresistant ES cells, xenografts, and relapsed human tumors. Joint suppression of these newfound targets, in concert with IGF-1R or mTOR blockade, should improve clinical outcomes.
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Journal: Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. (Pubmed Central) - Jul 15, 2017
P1
Dalotuzumab was well tolerated in paediatric patients with advanced solid malignancies. The RP2D of dalotuzumab is 900 mg/m(2) (ClinicalTrials.gov identifier: NCT01431547, Protocol PN062).
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial primary completion date, Metastases: Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038) (clinicaltrials.gov) - Apr 4, 2017
P2, N=7, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
The RP2D of dalotuzumab is 900 mg/m(2) (ClinicalTrials.gov identifier: NCT01431547, Protocol PN062). Trial primary completion date: Mar 2017 --> Sep 2017
- ||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment open: BIONICS Israel Trial (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=60, Recruiting, Sponsor: Medinol Ltd.
Trial primary completion date: Mar 2017 --> Sep 2017 Not yet recruiting --> Recruiting
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Phase classification, Trial primary completion date, Metastases: Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038) (clinicaltrials.gov) - Sep 2, 2016
P2, N=7, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P2 | Trial primary completion date: Aug 2016 --> Mar 2017
- ||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
New trial: BIONICS Israel Trial (clinicaltrials.gov) - Jul 15, 2016
P=N/A, N=60, Not yet recruiting, Sponsor: Medinol Ltd.
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial primary completion date, Metastases: Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038) (clinicaltrials.gov) - Mar 31, 2016
P=N/A, N=7, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Phase classification: P=N/A --> P2 | Trial primary completion date: Aug 2016 --> Mar 2017 Trial primary completion date: Mar 2016 --> Aug 2016
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion: AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) (clinicaltrials.gov) - Feb 27, 2016
P2, N=45, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Mar 2016 --> Aug 2016 Active, not recruiting --> Completed
- |||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Metastases: Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED) (clinicaltrials.gov) - Feb 27, 2016
P1/2, N=147, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Metastases: Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) (clinicaltrials.gov) - Feb 27, 2016
P2, N=216, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Metastases: Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) (clinicaltrials.gov) - Feb 27, 2016
P1, N=46, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment closed, Trial primary completion date: Angiography Study of BioNIR Drug Eluting Stent System (NIREUS) (clinicaltrials.gov) - Dec 23, 2015
P2, N=300, Active, not recruiting, Sponsor: Medinol Ltd.
No longer recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Oct 2015
- ||| Enrollment closed, Trial primary completion date: BIONICS: Study of BioNIR Drug Eluting Stent System in Coronary Stenosis (clinicaltrials.gov) - Dec 4, 2015
P2, N=1906, Active, not recruiting, Sponsor: Medinol Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Oct 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Aug 2016
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion: Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017) (clinicaltrials.gov) - Nov 19, 2015
P2, N=39, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Aug 2016 Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD), Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Trial primary completion date, Metastases: Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Nov 10, 2015
P1, N=16, Completed, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Mar 2014
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial primary completion date: Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids (clinicaltrials.gov) - Sep 24, 2015
P1, N=24, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Mar 2014 Trial primary completion date: Dec 2015 --> Apr 2016
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial primary completion date, Metastases: Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038) (clinicaltrials.gov) - Sep 24, 2015
P=N/A, N=7, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Dec 2015 --> Apr 2016 Trial primary completion date: Oct 2015 --> Mar 2016
- Zolinza (vorinostat) / Merck (MSD), Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial primary completion date, Metastases: Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Sep 8, 2015
P1, N=16, Active, not recruiting, Sponsor: Fox Chase Cancer Center
Trial primary completion date: Oct 2015 --> Mar 2016 Trial primary completion date: Dec 2014 --> Dec 2016
- ||| MK-2206 / Merck (MSD), Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Enrollment change, Metastases: Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049) (clinicaltrials.gov) - Aug 27, 2015
P1, N=65, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Dec 2014 --> Dec 2016 Active, not recruiting --> Completed | N=124 --> 65
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Metastases: Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) (clinicaltrials.gov) - Aug 25, 2015
P1, N=33, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed | N=124 --> 65 Active, not recruiting --> Completed
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion: Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) (clinicaltrials.gov) - Aug 17, 2015
P1, N=11, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed No longer recruiting --> Completed
- |||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion: Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) (clinicaltrials.gov) - Aug 17, 2015
P2, N=57, Completed, Sponsor: Merck Sharp & Dohme Corp.
No longer recruiting --> Completed Active, not recruiting --> Completed
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial primary completion date: Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids (clinicaltrials.gov) - Apr 23, 2015
P1, N=24, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Trial primary completion date: May 2015 --> Dec 2015
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Metastases: Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer (clinicaltrials.gov) - Feb 19, 2015
P2, N=35, Completed, Sponsor: NCIC Clinical Trials Group
Trial primary completion date: May 2015 --> Dec 2015 Active, not recruiting --> Completed
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial primary completion date, Metastases: Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038) (clinicaltrials.gov) - Feb 3, 2015
P=N/A, N=7, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Mar 2015
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment closed, Metastases: A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056) (clinicaltrials.gov) - Dec 24, 2014
P1, N=21, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Dec 2014 --> Mar 2015 Completed --> Active, not recruiting
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial primary completion date: Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids (clinicaltrials.gov) - Nov 18, 2014
P1, N=24, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Completed --> Active, not recruiting Trial primary completion date: Dec 2014 --> May 2015
- |||| Enrollment open: BIONICS: Study of BioNIR Drug Eluting Stent System in Coronary Stenosis (clinicaltrials.gov) - Aug 19, 2014
P2, N=1906, Recruiting, Sponsor: Medinol Ltd.
Trial primary completion date: Dec 2014 --> May 2015 Not yet recruiting --> Recruiting
- |||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment open: Angiography Study of BioNIR Drug Eluting Stent System (NIREUS) (clinicaltrials.gov) - Aug 19, 2014
P2, N=300, Recruiting, Sponsor: Medinol Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Zolinza (vorinostat) / Merck (MSD), Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment change, Metastases: Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Jun 18, 2014
P1, N=48, Active, not recruiting, Sponsor: Fox Chase Cancer Center
Not yet recruiting --> Recruiting N=25 --> 48
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment closed: Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids (clinicaltrials.gov) - Jan 14, 2014
P1, N=28, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=25 --> 48 Recruiting --> Active, not recruiting
- ||||| New P2 trial: BIONICS: Study of BioNIR Drug Eluting Stent System in Coronary Stenosis (clinicaltrials.gov) - Nov 24, 2013
P2, N=1906, Not yet recruiting, Sponsor: Medinol Ltd.
- ||||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
New P2 trial: Angiography Study of BioNIR Drug Eluting Stent System (NIREUS) (clinicaltrials.gov) - Nov 24, 2013
P2, N=300, Not yet recruiting, Sponsor: Medinol Ltd.
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Enrollment change, Monotherapy, Metastases: Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) (clinicaltrials.gov) - Nov 19, 2013
P1, N=21, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting N=60 --> 21
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Trial completion, Monotherapy, Metastases: Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) (clinicaltrials.gov) - Nov 19, 2013
P1, N=21, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=60 --> 21 Active, not recruiting --> Completed
- ||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Enrollment change, Combination therapy, Monotherapy: A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) (clinicaltrials.gov) - Nov 4, 2013
P2, N=115, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed N=352 --> 115
- |||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Trial completion, Combination therapy, Monotherapy: A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) (clinicaltrials.gov) - Nov 4, 2013
P2, N=115, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=352 --> 115 Active, not recruiting --> Completed
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment change, Metastases: A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056) (clinicaltrials.gov) - Sep 15, 2013
P1, N=21, Completed, Sponsor: Merck
Active, not recruiting --> Completed N=30 --> 21
- || MK-2206 / Merck (MSD), Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment closed, Metastases: Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049) (clinicaltrials.gov) - Sep 15, 2013
P1, N=124, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=30 --> 21 Recruiting --> Active, not recruiting
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Metastases: A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056) (clinicaltrials.gov) - Sep 15, 2013
P1, N=21, Completed, Sponsor: Merck
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD), Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment closed, Metastases: Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Jun 2, 2013
P1, N=48, Active, not recruiting, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- MK-2206 / Merck (MSD), Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Trial termination, Combination therapy, Metastases: A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) (clinicaltrials.gov) - May 1, 2013
P1, N=48, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; The study was terminated for business reasons and not due to any safety or efficacy concerns related to dalotuzumab.
- MK-2206 / Merck (MSD), Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Enrollment change, Combination therapy, Metastases: A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027) (clinicaltrials.gov) - May 1, 2013
P1, N=48, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Terminated; The study was terminated for business reasons and not due to any safety or efficacy concerns related to dalotuzumab. N=121 --> 48
- ||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Enrollment change: A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) (clinicaltrials.gov) - Apr 30, 2013
P2, N=84, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=121 --> 48 N=150 --> 84
- ||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD), dalotuzumab (MK 0646) / Merck (MSD), Pierre Fabre
Enrollment closed: A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064) (clinicaltrials.gov) - Apr 30, 2013
P2, N=84, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=150 --> 84 Recruiting --> Active, not recruiting
- ||| Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Enrollment change: A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination with Trastuzumab for Patients with HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (EUDRACT) - Apr 19, 2013
P2, N=66, Completed, Sponsor: Merck & Co, Inc.`ARIAD Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting N=22 --> 66
- | Taltorvic (ridaforolimus) / Takeda, Merck (MSD)
Trial completion, Metastases: Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1) (clinicaltrials.gov) - Apr 9, 2013
P2, N=50, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=22 --> 66 Active, not recruiting --> Completed
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD), Erbitux (cetuximab) / Eli Lilly
Trial termination, Metastases: Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer (clinicaltrials.gov) - Feb 21, 2013
P1, N=12, Terminated, Sponsor: Angela Taber MD
Active, not recruiting --> Completed Recruiting --> Terminated; Determination to stop enrollment made due to funding